Introduction:Since the beginning of the outbreak in China, ending 2019, the Novel Coronavirus has spread subsequently to the rest of the world causing an ongoing pandemic. The World Health Organisation (WHO) declared COVID-19 "a public health emergency of international concern." Taking into consideration the lockdown and quarantine situation, a research team of doctors from the Hospital of Salamanca, decided to do an evaluation of the current emotional state on the general population with a webbased survey in English and in Spanish, which was considered a useful and fast method that could help us determine how people perceived stress and worry due to the COVID-19. Methods: The survey included a 22 items, gathering information in 3 sections: Sociodemographic data, the Perceived Stress Scale (PSS-10) by Cohen and additional queries that assessed the current worry and change of behaviours due to this pandemic. Results: The survey received 1091 respondents from 41 countries, from March 17 to the 1 st of April, 2020. The mean age of the respondents was 43.1 (14.2) years old, and more than two thirds were women. 21.1% were health personnel. The mean of the PSS-10 score was 17.4 (6.4). Significantly higher scores were observed among women, youth, students, and among those who expressed concern and those who perceived increased susceptibility to the COVID-19. In contrast, no significant differences were observed between the health professionals and the general population. A weak correlation was observed between mean relative volume RSV of the last 28 days and the number of cases reported (rho = 0.31, p <0.001) and deaths (rho = 0.28, p <0.001). Discussion: With these results the researchers describe an increase of affective symptoms due to the COVID-19. This pandemic is raising the anxiety levels. The findings of the study show the affective and cognitive alterations people are going through. This survey is the first attempt to measure the psychological consequences this pandemic is having, in order to be able to provide the support to confront this global issue, addressing the mental health care that will be needed.

All-oral direct-acting antiviral drugs (DAAs) for hepatitis C virus, which have response rates of 95% or more, represent a major clinical advance. However, the high list price of DAAs has led many governments to restrict their reimbursement. We reviewed the availability of, and national criteria for, interferon-free DAA reimbursement among countries in the European Union and European Economic Area, and Switzerland. Reimbursement documentation was reviewed between Nov 18, 2016, and Aug 1, 2017. Primary outcomes were fibrosis stage, drug or alcohol use, prescriber type, and HIV co-infection restrictions. Among the 35 European countries and jurisdictions included, the most commonly reimbursed DAA was ombitasvir, paritaprevir, and ritonavir, with dasabuvir, and with or without ribavirin (33 [94%] countries and jurisdictions). 16 (46%) countries and jurisdictions required patients to have fibrosis at stage F2 or higher, 29 (83%) had no listed restrictions based on drug or alcohol use, 33 (94%) required a specialist prescriber, and 34 (97%) had no additional restrictions for people co-infected with HIV and hepatitis C virus. These findings have implications for meeting WHO targets, with evidence of some countries not following the 2016 hepatitis C virus treatment guidelines by the European Association for the Study of Liver.

Thus, there was a high frequency of psychotic symptoms after intravenous cocaine use; patients with psychotic symptoms reported higher use of cannabis and benzodiazepines in the previous month and lower use of methadone. More tremors and stereotyped movements were observed in the group with psychotic symptoms. It is necessary to give a special approach to cocaine intravenous users.